Be A Freedom Fighter · Bill Library
HR 10770 — 340B Rebate Model Delay Act
Freedom score: 0 (scale −10 to +10)
- Individual rights: 0
- Property rights: 0
- Economic freedom: -1
- Privacy & due process: 0
- Government power: +1
Sponsor: Rep. Bresnahan, Robert P. [R-PA-8] · Latest action: Referred to the House Committee on Energy and Commerce. (2026-10-09)
Full text on GovInfo (introduced version) · Congress.gov · ← Bill Library index
Findings — 5 highlighted provisions
Each item below is one provision documented in the findings file. The same provision is highlighted in the full text underneath, with its section citation and criterion. Everything else on this page is plain, unreviewed bill text.
- Sec. 1 — supplies the short title See in text ↓
- Sec. 2(a) · Economic Freedom — new Public Health Service Act §340B(a)(11) temporarily prohibits the HHS Secretary from entering manufacturer agreements under §340B(a)(1) that require covered entities other than those in §340B(a)(4)(E) to pay more at the point of purchase than the already applicable 340B ceiling price. This locks in upfront price protection for the covered entities during the stated period; it does not repeal the existing discounted-price program or simply ban every rebate arrangement outside its terms See in text ↓
- Sec. 2(a) · Economic Freedom — contains the literal time formulation "For the period beginning on January 1, 2027, the date of enactment of this paragraph, and ending on December 31, 2028". The juxtaposition of January 1, 2027 and "the date of enactment" is a drafting ambiguity, not an express later-of formula. The specified end is December 31, 2028; implementation timing is uncertain if enacted on another date See in text ↓
- Sec. 2(b) — independently says that, during the similarly specified period, HHS may not implement the specifically identified August 3, 2026 340B Rebate Model Pilot Program or any substantially similar program. The pilot notice had proposed manufacturer plans beginning January 1, 2027. The bill therefore delays an agency change in the manner of delivering the existing 340B discounts, rather than newly establishing free-market drug prices See in text ↓
- Sec. 2(a)–(b) · Economic Freedom — is time limited and restrains an agency and the manufacturer-agreement format; it does not change federal criminal law or enact a general pharmacy rebate ban See in text ↓
Full text (introduced version)
3 of 4 text blocks highlighted. Source: GovInfo, fetched cached.
SECTION 1. SHORT TITLE.
Sec. 1 — supplies the short title
SEC. 2. LIMITING USE OF REBATES UNDER THE 340B PROGRAM.
Sec. 2(a) · Economic Freedom — new Public Health Service Act §340B(a)(11) temporarily prohibits the HHS Secretary from entering manufacturer agreements under §340B(a)(1) that require covered entities other than those in §340B(a)(4)(E) to pay more at the point of purchase than the already applicable 340B ceiling price. This locks in upfront price protection for the covered entities during the stated period; it does not repeal the existing discounted-price program or simply ban every rebate arrangement outside its terms
Sec. 2(a) · Economic Freedom — contains the literal time formulation "For the period beginning on January 1, 2027, the date of enactment of this paragraph, and ending on December 31, 2028". The juxtaposition of January 1, 2027 and "the date of enactment" is a drafting ambiguity, not an express later-of formula. The specified end is December 31, 2028; implementation timing is uncertain if enacted on another date
Sec. 2(a)–(b) · Economic Freedom — is time limited and restrains an agency and the manufacturer-agreement format; it does not change federal criminal law or enact a general pharmacy rebate ban
Sec. 2(b) — independently says that, during the similarly specified period, HHS may not implement the specifically identified August 3, 2026 340B Rebate Model Pilot Program or any substantially similar program. The pilot notice had proposed manufacturer plans beginning January 1, 2027. The bill therefore delays an agency change in the manner of delivering the existing 340B discounts, rather than newly establishing free-market drug prices
Sec. 2(a)–(b) · Economic Freedom — is time limited and restrains an agency and the manufacturer-agreement format; it does not change federal criminal law or enact a general pharmacy rebate ban
Findings source: bill-scores-v2-batch42-findings-2026-11-15.md. Highlights come only from that file; no finding, score, or provision was invented for this page.
What you can do
Contact your U.S. Representative and Senators about this bill.
Find your Representative Contact your Senators
Spot an error on this page? Report it.